Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has ...

Humacyte (HUMA) announced the pricing of an underwritten public offering of 47.62M shares of its common stock at a public offering price of $1.05 per share. The gross proceeds from the offering are ...

The size and price of the stock offering were not disclosed.

On June 10, 2026, Humacyte reported positive top-line interim results from its Phase 3 V012 trial evaluating its acellular tissue engineered vessel (ATEV) for dialysis access in female patients with ...

Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity ...

Stock market movers today: futures rebound after AI sell-off as oil dips; see top gainers/losers like Navan, Oracle, Humacyte ...

The commercial-stage biotechnology platform company's acellular tissue engineered vessel had an average of 91 more catheter-free days compared to autologous arteriovenous fistula, the current standard ...

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is among the best penny stocks under $1 according to hedge funds. TheFly ...

Oxford Industries reported a lower profit, citing the effects of tariff costs and macroeconomic pressures weighing on consumer sentiment. Shares fell 8.7%, to $39.50, after the bell. Humacyte reported ...

Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was ...